We are proud to announce that Eagle IP was ranked in Tier 1 (the highest tier) for Patent Prosecution in the IP Stars 2025 Patent Firms Ranking by Managing IP. The rankings cover over 70 jurisdictions worldwide and recognize the top recommended firms for patent filing, prosecution, and disputes work. This Tier 1 placement is a testament to the positive feedback our clients have provided to Managing IP during their annual reviews.

It is with great pride that we have been included in this highest category among just a select few other top firms in Hong Kong. We are deeply grateful to Managing IP for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US and Chinese patent law, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas. 

Our Past Events

Recommended Insights

Updates on Hong Kong Patents Examination Guidelines in 2024

29 February 2024
The Intellectual Property Department of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China (HKIPD) has recently made several updates to the Hong Kong Patents Examination Guidelines, effective from 26 January, 2024. These changes mainly clarify and reflect the Registry’s current practices regarding patent examination for Standard Patent (R) […]
China Patent 2020 to 2021

China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021

23 April 2020
China continues to progress towards its major goal of significantly strengthening IP protection within its borders. Last year it announced several proposed amendments to its patent laws. In January 2020 China and the US signed the Economic and Trade Agreement between the Government of China and US (published 16 January 2020 –“Trade Agreement”), which detailed […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

29 April 2021
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

Narrow Claim Scope of a Chinese Utility Model Patent Fuels Design-Arounds by Failing to Curb Competing Products:

28 October 2020
Learning from a 2019 China’s Top 50 Representative IP Case The number of patent applications in China is now the highest in the world, with more than half the applications filed as utility model applications (UMs). For example, there were more than 2 million UMs filed in 2018 alone (for the difference between a utility […]
Top crossarrow-right